CN111448185A - 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法 - Google Patents

一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法 Download PDF

Info

Publication number
CN111448185A
CN111448185A CN201880078396.8A CN201880078396A CN111448185A CN 111448185 A CN111448185 A CN 111448185A CN 201880078396 A CN201880078396 A CN 201880078396A CN 111448185 A CN111448185 A CN 111448185A
Authority
CN
China
Prior art keywords
degrees
crystalline form
compound
formula
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880078396.8A
Other languages
English (en)
Inventor
陈正霞
张杨
戴美碧
程洪飞
杨素琴
李文举
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Zhenbao Pharmaceutical Co ltd
Original Assignee
Harbin Zhenbao Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Zhenbao Pharmaceutical Co ltd filed Critical Harbin Zhenbao Pharmaceutical Co ltd
Priority to CN202310259434.2A priority Critical patent/CN116283940A/zh
Publication of CN111448185A publication Critical patent/CN111448185A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一类作为FGFR和VEGFR抑制剂化合物的盐型、晶型、制备方法及其医药用途。

Description

PCT国内申请，说明书已公开。

Claims (63)

  1. PCT国内申请，权利要求书已公开。
CN201880078396.8A 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法 Pending CN111448185A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310259434.2A CN116283940A (zh) 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711286398X 2017-12-07
CN201711286398 2017-12-07
PCT/CN2018/119716 WO2019109995A1 (zh) 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310259434.2A Division CN116283940A (zh) 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN111448185A true CN111448185A (zh) 2020-07-24

Family

ID=66750401

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880078396.8A Pending CN111448185A (zh) 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
CN202310259434.2A Pending CN116283940A (zh) 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310259434.2A Pending CN116283940A (zh) 2017-12-07 2018-12-07 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法

Country Status (5)

Country Link
US (1) US11078194B2 (zh)
EP (1) EP3722282A4 (zh)
JP (1) JP6974618B2 (zh)
CN (2) CN111448185A (zh)
WO (1) WO2019109995A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230115528A1 (en) * 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Indazole compounds
EP4186894A4 (en) * 2020-08-11 2024-01-17 Henan Medinno Pharmaceutical Tech Co Ltd FGFR INHIBITOR COMPOUND AND ITS USE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729189A (zh) * 2002-12-20 2006-02-01 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3－d]嘧啶衍生物
CN101611014A (zh) * 2006-12-21 2009-12-23 阿斯利康(瑞典)有限公司 用作fgfr抑制剂的酰氨基吡唑类化合物
CN104507944A (zh) * 2012-05-30 2015-04-08 阿斯特克斯治疗有限公司 作为fgfr抑制剂的蝶啶
CN105906630A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2017024968A1 (zh) * 2015-08-07 2017-02-16 南京明德新药研发股份有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
CN107137407A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU9327501A (en) 2000-09-11 2002-03-26 Chiron Corp Quinolinone derivatives
AU2003241925A1 (en) 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729189A (zh) * 2002-12-20 2006-02-01 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3－d]嘧啶衍生物
CN101611014A (zh) * 2006-12-21 2009-12-23 阿斯利康(瑞典)有限公司 用作fgfr抑制剂的酰氨基吡唑类化合物
CN104507944A (zh) * 2012-05-30 2015-04-08 阿斯特克斯治疗有限公司 作为fgfr抑制剂的蝶啶
CN105906630A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2017024968A1 (zh) * 2015-08-07 2017-02-16 南京明德新药研发股份有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
CN107137407A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途

Also Published As

Publication number Publication date
US11078194B2 (en) 2021-08-03
CN116283940A (zh) 2023-06-23
US20200361913A1 (en) 2020-11-19
JP6974618B2 (ja) 2021-12-01
WO2019109995A1 (zh) 2019-06-13
EP3722282A4 (en) 2021-04-14
JP2021505625A (ja) 2021-02-18
EP3722282A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
TWI713655B (zh) 吡啶並[1,2-a]嘧啶酮類似物的晶型及其製備方法和中間體
EP4011867A1 (en) Crystal forms c and e of pyrazin-2(1h)-one compound and preparation method therefor
CN111448185A (zh) 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
CA3008689A1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
CN108349975B (zh) 4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体
US20220281853A1 (en) Crystal form d of pyrazine-2(1h)-ketone compound and preparation method therefor
US11603366B2 (en) Crystalline form and B crystalline form of pyrazine-2(1H)-ketone compound and preparation method thereof
WO2019114741A1 (zh) 作为Akt抑制剂的盐型及其晶型
WO2018214958A1 (zh) Ido1抑制剂的晶型及其制备方法
SG189931A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
WO2020164603A1 (zh) 固体形式的fgfr抑制剂化合物及其制备方法
CN111132983B (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
CN109563097A (zh) 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
WO2019085893A1 (zh) 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法
WO2022262841A1 (zh) 一种螺环化合物的盐型、晶型及其制备方法
WO2023246854A1 (zh) 一种硼酸酯衍生物的结晶、其制备方法及用途
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
WO2023143079A1 (zh) 化合物的晶型及其制备方法
US20230271978A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
US11136347B2 (en) Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof
WO2020088677A1 (zh) 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法
CN115836069A (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
CN115843298A (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN114945565A (zh) 一种吡咯烷基脲衍生物的晶型及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200724